212 related articles for article (PubMed ID: 34540710)
1. Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer.
Valerio L; Giani C; Agate L; Molinaro E; Viola D; Bottici V; Matrone A; Puleo L; Lorusso L; Cappagli V; Ribechini A; Elisei R
Eur Thyroid J; 2021 Jul; 10(5):399-407. PubMed ID: 34540710
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
Wirth LJ; Durante C; Topliss DJ; Winquist E; Robenshtok E; Iwasaki H; Luster M; Elisei R; Leboulleux S; Tahara M
Oncologist; 2022 Jul; 27(7):565-572. PubMed ID: 35482606
[TBL] [Abstract][Full Text] [Related]
3. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
4. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
5. Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial.
Dotinga M; Vriens D; van Velden FHP; Stam MK; Heemskerk JWT; Dibbets-Schneider P; Pool M; Rietbergen DDD; de Geus-Oei LF; Kapiteijn E
Diagnostics (Basel); 2022 Dec; 12(12):. PubMed ID: 36553163
[No Abstract] [Full Text] [Related]
6. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer.
Ferrari SM; Elia G; Ragusa F; Paparo SR; Mazzi V; Miccoli M; Galdiero MR; Varricchi G; Foddis R; Guglielmi G; Spinelli C; La Motta C; Benvenga S; Antonelli A; Fallahi P
Expert Opin Investig Drugs; 2021 Sep; 30(9):913-921. PubMed ID: 34428101
[TBL] [Abstract][Full Text] [Related]
8. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.
Balmelli C; Railic N; Siano M; Feuerlein K; Cathomas R; Cristina V; Güthner C; Zimmermann S; Weidner S; Pless M; Stenner F; Rothschild SI
J Cancer; 2018; 9(2):250-255. PubMed ID: 29344270
[No Abstract] [Full Text] [Related]
10. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
Nervo A; Ragni A; Gallo M; Ferraris A; Fonio P; Piovesan A; Arvat E
Thyroid; 2020 Feb; 30(2):229-236. PubMed ID: 31854230
[No Abstract] [Full Text] [Related]
13. Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice.
Capdevila J; Deandreis D; Durante C; Leboulleux S; Luster M; Netea-Maier R; Newbold K; Singer S; Sykiotis GP; Bartes B; Farnell K; Locati LD
Eur Thyroid J; 2023 Aug; 12(5):. PubMed ID: 37429326
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of lenvatinib in a series of advanced well-differentiated thyroid carcinomas from a single tertiary cancer center and literature review.
Damásio IL; Figueiredo A; Maciel J; Horta M; Silva TN; Simões-Pereira J; Donato S; Leite V
Minerva Endocrinol (Torino); 2024 Mar; ():. PubMed ID: 38512702
[TBL] [Abstract][Full Text] [Related]
15. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2019; 10():384. PubMed ID: 31244783
[No Abstract] [Full Text] [Related]
16. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
Tori M; Shimo T
BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review.
Sheu NW; Jiang HJ; Wu CW; Chiang FY; Chiou HC; Hsiao PJ
World J Surg Oncol; 2019 May; 17(1):84. PubMed ID: 31103041
[TBL] [Abstract][Full Text] [Related]
18. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
19. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer.
Lorusso L; Pieruzzi L; Biagini A; Sabini E; Valerio L; Giani C; Passannanti P; Pontillo-Contillo B; Battaglia V; Mazzeo S; Molinaro E; Elisei R
Onco Targets Ther; 2016; 9():6467-6477. PubMed ID: 27799794
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
[No Abstract] [Full Text] [Related]
[Next] [New Search]